PerQseal® Impella Early Feasibility Study

  • End date
    Mar 1, 2023
  • participants needed
  • sponsor
    Vivasure Medical Limited
Updated on 29 April 2022


The purpose of this Clinical Investigation Plan is to assess the initial feasibility results of the PerQseal® device, when used on this very specific Impella population. Safety and effectiveness will be assessed in patients where an Impella device was used for either cardiogenic shock or PPCI. Closure of femoral arterial access sites created with 13 to 14 F sheaths will be studied, assessing the need for alternative therapy other than manual compression or adjunctive endovascular ballooning.


This study is a prospective, multi-center, single arm EFS. Patients undergoing use of an Impella device for cardiogenic shock or PPCI, requiring an arteriotomy created by 13 to 14 F sheaths (arteriotomies up to approx. 18 F), via the common femoral artery will be screened against the study inclusion/exclusion criteria. If the patient meets study eligibility requirements, they shall be invited to participate, provide informed consent, and shall subsequently be assigned a study ID number. Enrollment will occur at the point where the PerQseal study device first enters the patient's body.

The planned enrollment is a minimum of 20 treated patients at a maximum of 5 study sites located in the United States.

Condition Percutaneous Large Hole Vascular Closure
Treatment PPCI, Cardiogenic shock, Cardiogenic shock
Clinical Study IdentifierNCT04818541
SponsorVivasure Medical Limited
Last Modified on29 April 2022


Yes No Not Sure

Inclusion Criteria

Age ≥ 19 years
Use of an Impella CP or 2.5 Impella device via the common femoral artery for protected percutaneous coronary intervention (PPCI) or cardiogenic shock
Duration of Impella use > 8 hours and ≤ 4 days if used for cardiogenic shock
Duration of Impella use ≤ 6 hours if used for PPCI
Impella access sheath between 13 and 14 F
Potential subject or authorized representative willing and able to provide appropriate study-specific informed consent
Females who are not pregnant or lactating and not planning to become pregnant for the duration of the study

Exclusion Criteria

Evidence of systemic bacterial or cutaneous infection, including groin infection
Known bleeding diathesis, definite or potential coagulopathy, platelet count < 100,000/µl or subjects on long term anticoagulants with an INR > 2 within 12 hours prior to index procedure
Significant anemia (hemoglobin <9 g/dL or hematocrit < 27%), within 24 hours prior to index procedure
Known type II heparin-induced thrombocytopenia
Unilateral or bilateral lower extremity amputation
Rest pain (e.g., Rutherford category 4 or greater), documented untreated iliac or common femoral artery diameter stenosis > 50% or previous bypass surgery/stent placement in the common femoral artery of target leg
Known existing nerve damage in the target leg
Known allergy to any of the materials used in the PerQseal® device (refer to Instructions for Use)
Subject unsuitable for surgical repair of the target leg access site
Subject has undergone a percutaneous procedure greater than 8 F sheath in the target leg, within the 90 days prior to index procedure
Subject has undergone a percutaneous procedure of 8 F sheath or less using an absorbable or suture mediated closure device for hemostasis, in the target vessel, within the 90 days prior to index procedure
Prior evidence of anterior calcification within 10 mm proximal or distal to arteriotomy site
Target femoral artery diameter is less than 6 mm in diameter
Subject is enrolled in another investigational medical device or drug study which has not completed the required primary endpoint follow-up
Subject has been previously enrolled in this clinical study
Current COVID-19 infection (with or without symptoms), recent positive test for COVID-19, or recent exposure to a person with COVID-19 infection
Procedural Exclusion Criteria
Initial common femoral arterial access achieved with manual palpation or blind arterial stick access, without use of an image guided approach (ultrasound or angiography)
Difficult dilation during initial target femoral artery access (e.g., that damages or kinks sheath dilators) while step-dilating up to the large-bore device
During arterial puncture, the target femoral artery suspected to have experienced a back arterial wall needle puncture or underwent > one needle puncture during the primary procedure,with a needle larger than a Micropuncture needle (18 gauge)
Subject has a tissue tract (i.e., estimated distance from skin entry point to arterial anterior surface at arteriotomy) expected to be greater than 8 cm
Significant blood loss/transfusion (defined as requiring transfusion of 4 or more units of blood products) during primary procedure or within 30 days prior to index procedure
Activated clotting time (ACT) > 300 seconds immediately prior to sheath removal or if ACT measurements are expected to be > 300 seconds for more than 24 hours after index procedure
Target puncture site is in a vascular graft
Target arteriotomy in the profunda femoris or superficial femoral artery or is in common femoral artery, but within 10 mm proximal of the bifurcation of the superficial femoral/ profunda femoris artery
Target arteriotomy located above the inferior epigastric artery and/or above the inguinal ligament based on bony landmarks
Subjects with an acute hematoma > 4 cm diameter, arteriovenous fistula, pseudoaneurysm, or intraluminal thrombosis at the target access site
Evidence of bleeding around the Impella sheath (BARC type 2 or higher)
Angiographic evidence of arterial laceration, dissection or stenosis within the femoral artery that would preclude use of the PerQseal® device
Uncontrolled hypertension (systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) just prior to planned vascular closure
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note